Advertisement
Canada markets open in 1 hour 32 minutes
  • S&P/TSX

    21,656.05
    +13.18 (+0.06%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • CAD/USD

    0.7274
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    82.33
    -0.36 (-0.44%)
     
  • Bitcoin CAD

    86,262.89
    +112.44 (+0.13%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,397.00
    +8.60 (+0.36%)
     
  • RUSSELL 2000

    1,947.95
    -19.53 (-0.99%)
     
  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,720.75
    +62.25 (+0.35%)
     
  • VOLATILITY

    17.86
    -0.35 (-1.92%)
     
  • FTSE

    7,866.96
    +18.97 (+0.24%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • CAD/EUR

    0.6811
    +0.0009 (+0.13%)
     

Could AstraZeneca and Sanofi Win Big in RSV?

AstraZeneca (NASDAQ: AZN) and its partner Sanofi (NASDAQ: SNY) recently announced promising results from a late-stage study of nirsevimab in preventing respiratory syncytial virus (RSV) in infants. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the two companies can win big with this experimental RSV therapy.